9 November 2017
EMA/CVMP/698114/2017
Committee for Medicinal Products for Veterinary Use

Opinion of the Committee for Medicinal Products for Veterinary Use on the establishment of maximum residue limits

Procedure no: EMEA/V/MRL/004113/FULL/0001

Name of the substance: Porcine prolactin (INN)

Basis for the opinion

Pursuant to Article 3 of Regulation (EC) No 470/2009 of 6 May 2009, Ryszka Florian "Biochefa" Pharmaceutical Research and Production Plant submitted to the European Medicines Agency on 4 September 2015 an application for the establishment of maximum residue limits for porcine prolactin.

On 21 January 2016 the Committee for Medicinal Products for Veterinary Use adopted a list of questions to be addressed by the applicant. The response to the list of questions was submitted on 10 May 2016.

Recommendation

The Committee, having considered the application and having evaluated the response to the list of questions, recommends by consensus the establishment of maximum residue limits for porcine prolactin in accordance with the following table:

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5545
Send a question via our website www.ema.europa.eu/contact

Pharmaco-logically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Porcine prolactin	NOT APPLICABLE	Porcine	No MRL required	NOT APPLICABLE	For oral use in newborn piglets at a dose of up to 0.2 mg /animal. For use in sows at a total dose of up to 5 mg /animal.	Agents acting on the reproductive system

The Norwegian CVMP member agrees with the above-mentioned recommendation of the Committee.

The scientific conclusions of the Committee are presented in the European public MRL assessment report (EPMAR), provided in Annex I of this opinion.

The present opinion is forwarded to the European Commission and to the applicant together with its appendices.

Annex I

European public MRL assessment report (EPMAR)